RPS6KA3 and cancer: Studies have demonstrated that RSK2, when activated by hypoxia or ERK signalling, influences cancer cell motility and invasion through multiple pathways17, including activating EMT-associated genes, modulating integrin activity, and reorganising the actin cytoskeleton.